Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Dublin, March 08, 2017 -- Research and Markets has announced the addition of the "The World Market for Personalized Medicine Tests for Cancer" report to their offering.
Personalized Medicine Tests for Cancer, provides an authoritative look at the market for companion and personalized medicine testing for cancer. The report includes a market size and forecast for personalized medicine testing by geography (US, EU, ROW). Company profiles are included and products are identified by status (on the market, in development)
Key Topics Covered:
Chapter One Executive Summary
- The Scourge of Cancer
- Definitions of Companion Diagnostics and Cancer Diagnostics
- Types of Tests Included
- Marketing Personalized Medicine-Based Cancer Tests
- Market
- Point of View
Chapter Two Introduction
- Cancer Treatments
- Cancer Risk Assessment
- Cancer Screening
- Cancer Monitoring
- Prognosis Assessment
- Technologies Used
- Immunoassays
- Immunohistochemistry (IHC)
- Flow Cytometry
- In Situ Hybridization
- Nucleic Acid Amplification Technologies
- Analysis of Gene Expression Patterns (Gene Signatures)
- Microarrays
- Sequencing Technologies
- Mass Spectrometry
- Liquid Biopsies
- Information Technology
- Test Targets
- HER2 Overexspression
- EGFR
- KRAS Mutations
- BRAF Mutations
- UGT1A1 Genetic Variants
- 5-Flurouracil Therapy
- PIK3CA Mutations
- KIF6 Mutations
- ALK Mutations
Chapter Three Market Analysis
- Products on the Market
- Market Analysis
- Drivers
- Diagnostic Companies and Pharmaceutical Companies
- Growth by Geography
Chapter Four Company Profiles.
- 20/20 GeneSystems, Inc.
- Abbott Laboratories
- ACT Genomics Co., Ltd.
- Adaptive Biotechnologies Corporation
- Admera Health (A GENEWIZ Company)
- Agena Bioscience Inc.
- Agendia NV
- Amoy Diagnostics Co., Ltd.
- ARKRAY, Inc.
- Biocartis
- bioMérieux SA
- Cepheid (Danaher)
- Genomic Health, Inc.
- Genoptix (A Novartis Company)
- Luminex Corporation
- Myriad Genetics, Inc.
- Qiagen N.V.
- QuanDx Inc.
- Quest Diagnostics
- Qvella Corporation
- RiboMed Biotechnologies, Inc.
- Roche
- Siemens Healthcare
- Symbiodx
- Theranostics Health Inc. (Acquired by Avant Diagnostics, Inc.)
- Thermo Fisher Scientific, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/778jp3/the_world_market
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Healthcare Services, Genomics, Diagnostics, Oncology Drugs
